The UK Competition Appeal Tribunal grants interim damages of £2 million in a case of abusive drugs price setting (Healthcare at Home / Genzyme)

Background GenzymeLimited ("Genzyme”) is the manufacturer of Ceredase and Cerezyme, drugs used in the treatment of Gaucher disease. Genzyme also provided home care services to administer its drugs. The home care services were initially subcontracted, firstly to Caremark and then to Healthcare at Home (“HH”). From April 2001, Genzyme provided home care services through its own integrated service - GenzymeHomecare. In May 2001, Genzyme terminated its contract with HH. From May 2001, HH (and other independent delivery/homecare service providers) were only able to obtain Cerezyme from Genzyme at the National Health Service (“NHS”) list price, which included the cost of the provision of homecare services. HH complained to the Office of Fair Trading (the "OFT") about Genzyme's pricing

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Hogan Lovells (London)

Quotation

Alexandra Brown, The UK Competition Appeal Tribunal grants interim damages of £2 million in a case of abusive drugs price setting (Healthcare at Home / Genzyme), 15 November 2006, e-Competitions November 2006, Art. N° 12650

Visites 6622

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues